Junshi Runjia (Shanghai) Pharmaceutical Technology Co., Ltd.

To evaluate the safety and tolerability of JS105 combined with other anti-tumor therapies in patients with advanced solid tumors To determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of JS105 combined with other anti-tumor therapies in patients with advanced solid tumors To evaluate the efficacy of JS105 combined with other anti-tumor therapies in patients with advanced solid tumors To evaluate the pharmacokinetic (PK) characteristics of JS105 combined with other anti-tumor therapies in patients with advanced solid tumors To explore the consistency of PIK3CA mutation detection in peripheral blood and tissue detection and its correlation with efficacy

Phase Ia: Evaluate the safety and tolerability of RP903 monotherapy in patients with advanced malignancies, MTD or MAD and DLT; determine RP2D and dosing regimen. Phase Ib: Evaluate the ORR of RP903 in the presence of PIK3CA mutations; evaluate the safety and tolerability of RP903. Secondary objectives: Evaluate the pharmacokinetic (PK) characteristics of RP903 monotherapy in patients with advanced malignancies; preliminarily evaluate the effectiveness of RP903 in the treatment of advanced malignancies. Exploratory objectives: Explore the correlation between PD characteristics and efficacy. Explore the feasibility of using peripheral blood instead of tumor tissue for PIK3CA mutation detection.